Cargando…

Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy

BACKGROUND: We assessed the role of adjuvant intensity-modulated radiotherapy (IMRT) in combination with chemotherapy for pancreatic carcinomas after curative resection and identified prognostic factors related to pancreatic carcinoma after multidisciplinary treatment strategies. MATERIAL/METHODS: P...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Ningyi, Wang, Zheng, Zhao, Jiandong, Long, Jiang, Xu, Jin, Ren, Zhigang, Jiang, Guoliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443358/
https://www.ncbi.nlm.nih.gov/pubmed/28512284
http://dx.doi.org/10.12659/MSM.904393
_version_ 1783238553252134912
author Ma, Ningyi
Wang, Zheng
Zhao, Jiandong
Long, Jiang
Xu, Jin
Ren, Zhigang
Jiang, Guoliang
author_facet Ma, Ningyi
Wang, Zheng
Zhao, Jiandong
Long, Jiang
Xu, Jin
Ren, Zhigang
Jiang, Guoliang
author_sort Ma, Ningyi
collection PubMed
description BACKGROUND: We assessed the role of adjuvant intensity-modulated radiotherapy (IMRT) in combination with chemotherapy for pancreatic carcinomas after curative resection and identified prognostic factors related to pancreatic carcinoma after multidisciplinary treatment strategies. MATERIAL/METHODS: Pancreatic carcinoma patients (n=61) who received adjuvant radiotherapy after resection (median dose, 50.4 Gy) between 2010 and 2016 were retrospectively identified. Sixty patients received chemotherapy, including concurrent chemoradiotherapy (CCRT), systemic chemotherapy, and regional intra-arterial infusion chemotherapy (RIAC). The Kaplan-Meier method was used to measure the 3-year overall survival (OS) and disease-free survival (DFS) rates. Log-rank univariate analysis and multivariate Cox regression model analysis were used to identify prognostic factors. RESULTS: Median follow-up time was 25.5 (range, 4.9–59.7) months. The 3-year OS and DFS rates were 31.0% and 16.1%, respectively. The median OS and DFS were 27.4 and 16.7 months, respectively. Multivariate analysis indicated that independent favorable predictors for OS were CCRT (p=0.039) and postoperative RIAC (p=0.044). Moreover, postoperative RIAC (p=0.027), and pre-radiotherapy CA19-9 ≤37 U/mL (p=0.0080) were independent favorable predictors for DFS. The combination of radiotherapy and chemotherapy was tolerated well by the patients, and no treatment-related death occurred. CONCLUSIONS: Combined IMRT and adjuvant chemotherapy appeared safe and effective for pancreatic carcinoma. CCRT was associated with improved survival with acceptable toxicity. We propose that radiotherapy could be a part of postoperative treatment, but it should be administered concurrently with chemotherapy. Adding RIAC was associated with improved OS and DFS and it could be integrated into the postoperative treatment regimen.
format Online
Article
Text
id pubmed-5443358
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-54433582017-06-05 Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy Ma, Ningyi Wang, Zheng Zhao, Jiandong Long, Jiang Xu, Jin Ren, Zhigang Jiang, Guoliang Med Sci Monit Clinical Research BACKGROUND: We assessed the role of adjuvant intensity-modulated radiotherapy (IMRT) in combination with chemotherapy for pancreatic carcinomas after curative resection and identified prognostic factors related to pancreatic carcinoma after multidisciplinary treatment strategies. MATERIAL/METHODS: Pancreatic carcinoma patients (n=61) who received adjuvant radiotherapy after resection (median dose, 50.4 Gy) between 2010 and 2016 were retrospectively identified. Sixty patients received chemotherapy, including concurrent chemoradiotherapy (CCRT), systemic chemotherapy, and regional intra-arterial infusion chemotherapy (RIAC). The Kaplan-Meier method was used to measure the 3-year overall survival (OS) and disease-free survival (DFS) rates. Log-rank univariate analysis and multivariate Cox regression model analysis were used to identify prognostic factors. RESULTS: Median follow-up time was 25.5 (range, 4.9–59.7) months. The 3-year OS and DFS rates were 31.0% and 16.1%, respectively. The median OS and DFS were 27.4 and 16.7 months, respectively. Multivariate analysis indicated that independent favorable predictors for OS were CCRT (p=0.039) and postoperative RIAC (p=0.044). Moreover, postoperative RIAC (p=0.027), and pre-radiotherapy CA19-9 ≤37 U/mL (p=0.0080) were independent favorable predictors for DFS. The combination of radiotherapy and chemotherapy was tolerated well by the patients, and no treatment-related death occurred. CONCLUSIONS: Combined IMRT and adjuvant chemotherapy appeared safe and effective for pancreatic carcinoma. CCRT was associated with improved survival with acceptable toxicity. We propose that radiotherapy could be a part of postoperative treatment, but it should be administered concurrently with chemotherapy. Adding RIAC was associated with improved OS and DFS and it could be integrated into the postoperative treatment regimen. International Scientific Literature, Inc. 2017-05-17 /pmc/articles/PMC5443358/ /pubmed/28512284 http://dx.doi.org/10.12659/MSM.904393 Text en © Med Sci Monit, 2017 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Clinical Research
Ma, Ningyi
Wang, Zheng
Zhao, Jiandong
Long, Jiang
Xu, Jin
Ren, Zhigang
Jiang, Guoliang
Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy
title Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy
title_full Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy
title_fullStr Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy
title_full_unstemmed Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy
title_short Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy
title_sort improved survival in patients with resected pancreatic carcinoma using postoperative intensity-modulated radiotherapy and regional intra-arterial infusion chemotherapy
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443358/
https://www.ncbi.nlm.nih.gov/pubmed/28512284
http://dx.doi.org/10.12659/MSM.904393
work_keys_str_mv AT maningyi improvedsurvivalinpatientswithresectedpancreaticcarcinomausingpostoperativeintensitymodulatedradiotherapyandregionalintraarterialinfusionchemotherapy
AT wangzheng improvedsurvivalinpatientswithresectedpancreaticcarcinomausingpostoperativeintensitymodulatedradiotherapyandregionalintraarterialinfusionchemotherapy
AT zhaojiandong improvedsurvivalinpatientswithresectedpancreaticcarcinomausingpostoperativeintensitymodulatedradiotherapyandregionalintraarterialinfusionchemotherapy
AT longjiang improvedsurvivalinpatientswithresectedpancreaticcarcinomausingpostoperativeintensitymodulatedradiotherapyandregionalintraarterialinfusionchemotherapy
AT xujin improvedsurvivalinpatientswithresectedpancreaticcarcinomausingpostoperativeintensitymodulatedradiotherapyandregionalintraarterialinfusionchemotherapy
AT renzhigang improvedsurvivalinpatientswithresectedpancreaticcarcinomausingpostoperativeintensitymodulatedradiotherapyandregionalintraarterialinfusionchemotherapy
AT jiangguoliang improvedsurvivalinpatientswithresectedpancreaticcarcinomausingpostoperativeintensitymodulatedradiotherapyandregionalintraarterialinfusionchemotherapy